News – Freeline

Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call

Freeline to Participate in Upcoming Investor Conferences

Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease

Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease

Freeline to Present at 2023 Jefferies Healthcare Conference

Freeline Reports First Quarter 2023 Financial Results and Business Highlights

Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

Freeline Completes ADS Ratio Change